GlassScriptPhysician profile
Alexander R Coltoff
NPI 1588026736
$51,192.83
in general payments reported to CMS, 2019-2025
15 companies · $47K in 2025
The $47K reported for 2025 was more than what 96% of Hematology & Oncology providers received nationally (typical 2025 total: $686).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $247 · 2022: $1,175 · 2023: $522 · 2024: $2,084 · 2025: $47K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $22K · Consulting Fee: $12K · Honoraria: $7,872 · Travel and Lodging: $3,783 · Education: $2,365 · Food and Beverage: $1,441.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $22,375.00 |
| Consulting Fee | $11,935.00 |
| Honoraria | $7,872.00 |
| Travel and Lodging | $3,783.11 |
| Education | $2,365.27 |
| Food and Beverage | $1,440.51 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sanofi US Services INC. | $18,109.05 | 2025 | |
| Sobi, INC | $13,398.02 | 2024-2025 | |
| Blueprint Medicines Corporation | $6,581.38 | 2023-2025 | Ayvakit |
| Incyte Corporation | $6,175.82 | 2023-2025 | Jakafi, Jakafi |
| Pharmaessentia USA Corporation | $4,964.97 | 2025 | Besremi |
| Adaptive Biotechnologies Corporation | $800.00 | 2022 | |
| Daiichi Sankyo INC. | $401.30 | 2021-2023 | |
| Genzyme Corporation | $226.00 | 2021-2025 | |
| Servier Pharmaceuticals LLC | $134.72 | 2023 | |
| Alexion Pharmaceuticals, INC. | $125.00 | 2022 | |
| Abbvie INC. | $114.02 | 2023 | Venclexta |
| Janssen Scientific Affairs, LLC | $86.56 | 2024 | Talvey, Carvykti, Darzalex |
| Apellis Pharmaceuticals, INC. | $45.27 | 2025 | Empaveli |
| Novartis Pharmaceuticals Corporation | $30.72 | 2024 |
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Alexander Coltoff listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.